Rafferty Asset Management LLC Buys Shares of 17,716 LENZ Therapeutics, Inc. (NASDAQ:LENZ)

Rafferty Asset Management LLC bought a new stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 17,716 shares of the company's stock, valued at approximately $511,000. Rafferty Asset Management LLC owned 0.06% of LENZ Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of LENZ Therapeutics during the 4th quarter worth about $29,000. SG Americas Securities LLC lifted its position in shares of LENZ Therapeutics by 20.7% during the fourth quarter. SG Americas Securities LLC now owns 5,458 shares of the company's stock valued at $158,000 after purchasing an additional 935 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in LENZ Therapeutics by 14.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,914 shares of the company's stock worth $229,000 after purchasing an additional 1,005 shares during the last quarter. Rhumbline Advisers grew its position in LENZ Therapeutics by 6.2% in the 4th quarter. Rhumbline Advisers now owns 18,754 shares of the company's stock worth $541,000 after purchasing an additional 1,100 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in shares of LENZ Therapeutics by 162.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company's stock worth $54,000 after buying an additional 1,151 shares in the last quarter. Institutional investors and hedge funds own 54.32% of the company's stock.

Analyst Ratings Changes

A number of analysts recently commented on LENZ shares. Citigroup increased their price target on LENZ Therapeutics from $44.00 to $47.00 and gave the company a "buy" rating in a research report on Thursday, March 20th. HC Wainwright reaffirmed a "buy" rating and issued a $38.00 price objective on shares of LENZ Therapeutics in a research report on Thursday, May 8th. Piper Sandler started coverage on shares of LENZ Therapeutics in a research note on Monday, April 14th. They set an "overweight" rating and a $51.00 price target for the company. Finally, TD Cowen started coverage on shares of LENZ Therapeutics in a research report on Tuesday, March 18th. They set a "buy" rating and a $60.00 target price for the company. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $46.60.

LENZ Therapeutics Trading Down 1.5%

LENZ stock traded down $0.44 during midday trading on Wednesday, hitting $28.96. The company had a trading volume of 27,313 shares, compared to its average volume of 183,306. The stock has a market cap of $815.11 million, a price-to-earnings ratio of -16.37 and a beta of 0.41. LENZ Therapeutics, Inc. has a 52 week low of $14.42 and a 52 week high of $38.93. The stock's 50 day moving average price is $25.56 and its 200 day moving average price is $27.23.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.55) by $0.02. Analysts predict that LENZ Therapeutics, Inc. will post -2.18 earnings per share for the current year.

LENZ Therapeutics Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.